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Editorial Comment
Urgent Parenteral Digoxin
Therapy: A Requiem*
GORDON A. EWY, MD, FACC
Tucson, Arizona
For more than 2 centuries the inotropic properties of the
digitalis glycosides have been used in the treatment of heart
failure, and their vagotonic effects have been used to control
the ventricular response rate in selected supraventricular
tachyarrhythmias. Digoxin is by far the most widely used
form of digitalis, predominantly because its relatively short
half-life results in a shorter period of digitalis toxicity when
this complication occurs. The elucidation of digoxin's phar-
macokinetics, the availability of plasma digoxin assays and
an increased appreciation of not only digoxin-drug interac-
tions but also the clinical settings that predispose to digitalis
sensitivities (1,2) have allowed this important cardiovascular
drug to be used with increasing safety.
Parenteral digoxin preparations have been available for
decades. Because of the alcoholic base, intramuscular injec-
tions of digoxin are extremely painful, and therefore, intra-
venous administration is the only acceptable parenteral
route. Because only 70% to 80% of oral digoxin is absorbed,
the estimated intravenous dose should be decreased accord-
ingly (1).
Intravenous digoxin versus beta-blockers and calcium
channel antagonists in atrial flutter and fibrillation. In the
past, because intravenous digoxin slows the frequency with
which impulses are conducted to the ventricles, it was
frequently used in the urgent treatment of patients with
selected supraventricular tachyarrhythmias, such as atrial
flutter or atrial fibrillation with a rapid ventricular response,
especially those with hemodynamic embarrassment. Intra-
venous digoxin was also used to break paroxysmal su-
praventricular tachycardia or to enhance the effectiveness of
carotid sinus pressure in terminating these tachyarrhyth-
mias. However, because of our present better understanding
of the pathophysiology and hemodynamic alterations asso-
ciated with these conditions, the urgent administration of
intravenous digoxin is seldom, if ever, indicated. The avail-
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ability of intravenous calcium channel and beta-adrenergic
blockers and the recent release of the ultrashort-acting
muscarinic agonist adenosine (3,4) have obviated the need
for intravenous digoxin in patients with paroxysmal su-
praventricular tachycardia.
Although digoxin is traditionally used to slow the ventric-
ular response rate to chronic atrial fibrillation and flutter,
predominantly by increasing vagal tone, it is not very
effective in the acute setting. Impulse conduction through
the atrioventricular (AV) node is influenced not only by
vagal tone but also by sympathetic tone. Because of the
enhanced impulse conduction that results from increased
sympathetic tone, digoxin alone is ineffective in slowing the
rate of AV node conduction in clinical settings associated
with increased sympathetic tone, although these are the very
situations in which one would consider the use of intrave-
nous digoxin. In these situations, intravenous beta-blocking
agents are more effective in slowing the ventricular response
rate. In patients with bronchospastic disease, intravenous
calcium channel blockers may be the drugs of choice. In
patients with hypotension or severe heart failure, urgent
cardioversion may be indicated. Digoxin will slow the ven-
tricular response rate to atrial fibrillation in a patient without
enhanced sympathetic tone at rest, but once the patient
begins walking, the ventricular response is again rapid,
unless there is AV node disease or concomitant administra-
tion of a calcium channel or beta-adrenergic blocker (5).
There is no correlation between the ventricular response rate
to atrial fibrillation and the serum digoxin level (6).
Intravenous digoxin versus dobutamine, nitroglycerin and
nitroprusside in heart failure. Likewise, urgent intravenous
digoxin is seldom if ever indicated in the management of
patients with acute heart failure (7). One concern with the
administration of intravenous glycosides to such patients has
been the reports that peripheral vasoconstriction may occur
before onset of the glycoside's positive inotropic effect (8,9).
Powell et al. (10) in their study of acute myocardial uptake of
digoxin in humans, which appears in this issue of the
Journal, did not find an increase in systemic vascular resis-
tance in their subjects (i.e., patients without heart failure).
Whether this observation applies to patients with acute or
severe congestive heart failure is unknown. The study of
Powell et al. (10) showed that the maximal effect of AV node
function (neural effect) occurred 12 min after intravenous
digoxin administration, whereas the positive inotropic effect
increased progressively for 27 min. This excellent study
showed that the positive inotropic effect correlated with
myocardial uptake, but the effect of AV conduction did not,
indicating a dissociation of intravenous digoxin's inotropic
and neural effects.
Although this information is important to our understand-
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ing of intravenous digoxin therapy, its clinical utility is not
great in the 1990s. More important in the urgent management
of patients with heart failure is the availability of rapid and
shorter-acting intravenous drugs such as dobutamine that
have a positive inotropic effect and drugs such as nitroglyc-
erin and nitroprusside that lower preload and afterload.
Intravenous digoxin in patients who cannot take oral
medications. Intravenous digoxin is appropriately and fre-
quently used when it is indicated in the hospitalized patient
who cannot take oral medications, However, now that safer
and more effective modes of therapy are available, it is time
for a requiem on the urgent intravenous administration of
digoxin.
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